Effect of Tutengcao granules on MSU-induced acute gouty arthritis in rabbits

doi:10.19803/j.1672-8629.20230619

Abstract

Abstract: Objective To observe the pharmacodynamic effect of Tutengcao granules (TTC) on monosodium urate-induced acute gouty arthritis model in rabbits. Methods Male Japanese big-eared white rabbits were randomly divided into normal control group, model control group, colchicine group (0.18 mg·kg^-1), high (600 mg·kg^-1), medium (300 mg·kg^-1) and (150 mg·kg^-1) low-dose groups. An acute gouty arthritis model was established by injecting monosodium urate (MSU) into the knee joint cavity of the left hind limb of rabbits. Five days after injection, synovial fluid was collected. The number of white blood cells in joint effusion was detected, and the contents of inflammatory cytokines interleukin-6 (IL-6), interleukin-8 (IL-8), tumor necrosis factor-α (TNF-α), interleukin-1β (IL-1β), and prostaglandin E2 (PGE2) in joint fluid were measured. Blood was collected to detect the blood uric acid value, and the serum urea, cholesterolesterol (CHO), serum creatinine (Cre), glucose (GLU) and triglyceride contents (TG) before and after administration. Results The number of white blood cells in the joint cavity of the TTC high, medium and low dose groups all decreased after 5 days of administration, and there was a significant difference between the medium dose group and the model control group (P<0.01). TTC high- and medium-dose groups tended to reduce blood uric acid. TTC had no effect on the contents of UREA, CHO, Cre, GLU and TG in rabbit serum. Compared with the model control group, the contents of IL-6, IL-8, TNF-α and PGE2 in the high, medium and low dose groups of TTC were significantly reduced. Among them, the contents of IL-6 and TNF-α in the high, medium and low dose groups were significantly reduced. There was a significant difference between the IL-8 content in the high-dose group and the medium-dose group and the PGE2 content in the middle-dose group (P<0.01). TTC high, medium and low dose groups can reduce the IL-1β content in synovial fluid to a certain extent. Conclusion TTC has a significant therapeutic effect on the MSU-induced acute arthritis rabbit model. It can reduce the number of white blood cells in the animal’s joint cavity, inhibit the expression of inflammatory cytokines, and reduce the uric acid content in the serum.

Key words: Tutengcao granules, monosodium urate, acute gouty arthritis, pharmacodynamics, big-eared rabbits, interleukin-6, interleukin-8, tumour necrosis factor-α

CLC Number:

YAO Rongmei, MAO Xin, XU Yingli, ZHANG Zhibin, GAO Yingjie, BAO Lei, BAO Yanyan, MENG Fengxian, CUI Xiaolan. Effect of Tutengcao granules on MSU-induced acute gouty arthritis in rabbits[J]. Chinese Journal of Pharmacovigilance, 2024, 21(3): 263-268.

Add to citation manager EndNote|Ris|BibTeX

URL: https://www.zgywjj.com/EN/10.19803/j.1672-8629.20230619

https://www.zgywjj.com/EN/Y2024/V21/I3/263

References

[1] GHAEMI-OSKOUIE F, SHI Y.The role of uric acid as an endogenous danger signal in immunity and inflammation[J]. Current Rheumatology Reports, 2011, 13(2): 160-166.
[2] KRISHNAN E, LIENESCH D, KWOH CK.Gout in ambulatory care settings in the United States[J]. The Journal of Rheumatology, 2008, 35(3): 498-501.
[3] KEENAN RT.The biology of urate[J]. Seminars in Arthritis and Rheumatism, 2020, 50(3S): 2-10.
[4] BARDIN T, RICHETTE P.Definition of hyperuricemia and gouty conditions[J]. Current Opinion in Rheumatology, 2014, 26(2): 186-191.
[5] RODDY E, DOHERTY M.Epidemiology of gout[J]. Arthritis Research & Therapy, 2010, 12(6): 223.
[6] SINGH JA, GAFFO A.Gout epidemiology of comorbidities[J]. Seminars in Arthritis and Rheumatism, 2020, 50(3S): 11-16.
[7] DHANASEKAR C, RASOOL M.Morin, a dietary bioflavonol, suppresses monosodium urate crystal-induced inflammationin an animal model of acute gouty arthritis with reference to NLRP3 inflammasome, hypo-xanthine phospho-ribosyltransferase, and inflammatory mediators[J]. European Journal of Pharmacology, 2016, 786: 116-127.
[8] COBO I, CHENG A, MURILLO-SAICH, et al.Monosodium urate crystals regulate a unique JNK-dependent macrophage metabolic and inflammatory response[J]. Cell Reports, 2022, 38(10): 110489.
[9] HOFFMAN HM, SCOTT P, MUELLER JL, et al.Role of the leucine-rich repeat domain of cryopyrin/NALP3 in monosodium urate crystal-induced inflammation in mice[J]. Arthritis and Rheumatology, 2010, 62(7): 2170-2179.
[10] MCDERMOTT MF, KINGSBURY SR, CONAGHAN PG.The role of the NLRP3 inflammasome in gout[J]. Journal of Inflammation Research, 2011, 4(4): 39-49.
[11] LIU YR, WANG JQ, LI J.Role of NLRP3 in the pathogenesis and treatment of gout arthritis[J]. Frontiers in Immunology, 2023, 14: 1137822.
[12] KIM Y, OH HC, PARK JW, et al.Diagnosis and treatment of inflammatory joint disease[J]. Hip & Pelvis, 2017, 29(4): 211-222.
[13] HUANG J, ZHU M, TAO Y, et al.Therapeutic properties of quercetin on monosodium urate crystal-induced inflammation in rat[J]. Journal of Pharmacy and Pharmacology, 2012, 64(8): 1119-1127.
[14] REES F, HUI M, DOHERTY M.Optimizing current treatment of gout[J]. Nature Reviews Rheumatology, 2014, 10(5): 271-283.
[15] FATTORI V, ZARPELON AC, STAURENGO-FERRARI L, et al.Budlein A, a sesquiterpene lactone from viguiera robusta, alleviates pain and inflammation in a model of acute gout arthritis in mice[J]. Frontiers in Pharmacology, 2018, 9: 1076.
[16] JIANG Y, YOU XY, FU KL, et al.Effects of extract from mangifera indica leaf on monosodium urate crystalinduced gouty arthritis in rats[J]. Evidence-Based Complementary and Alternative Medicine, 2012, 967573: 6.
[17] YUAN X, FAN YS, XU L, et al.Jia-Wei-Si-Miao-Wan alleviates acute gouty arthritis by targeting NLRP3 inflammasome[J]. Journal of Biological Regulators & Homeostatic Agents, 2019, 33(1): 63-71.
[18] KIM SK.The mechanism of the NLRP3 inflammasome activation and pathogenic implication in the pathogenesis of gout[J]. International Journal of Rheumatic Diseases, 2022, 29(3): 140-153.
[19] ZHANG HH, BU XW, ZHANG JP, et al.Efficacy of Tutengcao decoction in the treatment of acute gouty arthritis with syndrome of exuberance of heat-toxin and blockade of static blood and turbidity[J]. China Medical Herald, 2019, 16(16): 116-119.
[20] MURUNIKKARA V, RASOOL M.Trikatu, a herbal compound that suppresses monosodium urate crystal-induced inflammation in rats, an experimental model for acute gouty arthritis[J]. Cell Biochemistry and Function, 2014, 32(1): 106-114.
[21] POPA-NITA O, NACCACHE PH.Crystal-induced neutrophil activation[J]. Immunology and Cell Biology, 2010, 88(1): 32-40.
[22] DE AL, DEVIS S, INDRAMOHAN M, et al.POP1 inhibits MSU-induced inflammasome activation and ameliorates gout[J]. Frontiers in Immunology, 2022, 13: 912069.
[23] CHEN L, MOLA M, DENG X, et al.Dolichos falcata Klein attenuated the inflammation induced by monosodium urate crystals in vivo and in vitro[J]. Journal of Ethnopharmacology, 2013, 150(2): 545-552.
[24] DHANASEKAR C, KALAISELVAN S, RASOOL M.Morin, a bioflavonoid suppresses monosodium urate crystal-induced inflammatory immune response in RAW 264.7 macrophages through the inhibition of inflammatory mediators, intracellular ROS levels and NF-κB activation[J]. PLoS One, 2015, 10(12): e0145093.
[25] CHENG JJ, MA XD, AI GX, et al.Palmatine protects against MSU-Induced gouty arthritis via regulating the NF-κB/NLRP3 and Nrf2 Pathways[J]. Drug Design Development Therapy, 2022, 16: 2119-2132.
[26] MITROULIS I, KAMBAS K, RITIS K.Neutrophils, IL-1β, and gout: is there a link[J]. Seminars in Immunopathology, 2013, 35(4): 501-512.
[27] RYCKMAN C, MCCOLL SR, VANDAL K, et al.Role of S100A8 and S100A9 in neutrophil recruitment in response to monosodium urate monohydrate crystals in the air-pouch model of acute gouty arthritis[J]. Arthritis & Rheumatism, 2003, 48(8): 2310-2320.
[28] MANSOUR AA, RAUCCI F, SAVIANO A, et al.Galectin-9 regulates monosodium urate crystal-induced gouty inflammation through the modulation of Treg/Th17 ratio[J]. Frontiers in Immunology, 2021, 12: 762016.
[29] POPE RM, TSCHOPP J.The role of interleukin-1 and the inflammasome in gout: implication for therapy[J]. Arthritis & Rheumatism, 2007, 56(10): 3183-3188.
[30] VARGAS-SANTOS AB, NEOGI T.Management of gout and hyperuricemia in CKD[J]. American Journal of Kidney Diseases, 2017, 70(3): 422-439.
[31] GHERGHINA ME, PERIDE I, TIGLIS M, et al.Uric acid and oxidative stress-relationship with cardiovascular, metabolic, and renal impairment[J]. International Journal of Molecular Sciences, 2022, 23(6): 3188.